SpyGlass Pharma, Inc. SGP

Annual Quarterly

No annual revenue total was found in SpyGlass Pharma, Inc.'s SEC filings.

SpyGlass Pharma, Inc. (SGP) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. Free cash flow was -$33.5 million. As of Jun 30, 2026 it held $223.1 million in cash and investments and $1.6 million in total debt.

Revenue
—
Net income
$-39.87M
Operating cash flow
$-32.70M
Free cash flow
$-33.49M
EPS
$-17.98
Dividend per share
None
Shares outstanding
33.43M
Net cash
$221.51M
as of Jun 30, 2026
Operating margin
—

Company profile

Industry
Surgical & Medical Instruments & Apparatus (SIC 3841)
Listed as
SGP (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Irvine, CA
SEC filer status
, Emerging growth company
SEC CIK
1778922
Former names
SpyGlassPharma, Inc. (until Jun 5, 2025); SpyGlass Ophthalmics, Inc. (until Jan 5, 2021)

Other Surgical & Medical Instruments & Apparatus companies

All 151 Surgical & Medical Instruments & Apparatus companies

Key figures

Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.

FY 2025
Dec 31, 2025
Operating income
-$41.4M
Net income
-$39.9M
Diluted EPS
-$17.98
Operating cash flow
-$32.7M
Free cash flow
-$33.5M
Total assets
$115.9M
Total liabilities
$10.2M
Stockholders' equity
-$98.8M
Cash and investments
$96.4M
Total debt
$1.6M

Recent SEC filings

Form Description Filed Period
8-K Current report
Other events
 Oct 19, 2026 Oct 19, 2026
8-K Current report
Regulation FD disclosure, Other events
 Oct 1, 2026 Oct 1, 2026
10-Q Quarterly report Aug 6, 2026 Jun 30, 2026
8-K Current report
Results of operations
 Aug 6, 2026 Aug 6, 2026
10-Q Quarterly report May 14, 2026 Mar 31, 2026
8-K Current report
Results of operations
 May 14, 2026 May 14, 2026

All 92 SpyGlass Pharma, Inc. SEC filings

Source: SEC EDGAR filings. This is company-reported data, not investment advice.